As treatment guidelines are constantly being updated to account for new treatment options for psoriatic arthritis (PsA), researchers of a new study in Joint Bone Spine have outlined recommendations by ...

Combination therapy with ixekizumab and tirzepatide bested monotherapy with ixekizumab alone in both psoriatic arthritis and ...

Most patients with psoriatic arthritis (PsA) failed to achieve low disease activity after switching from one targeted therapy to another, real-world data from Scandinavian registries indicated.

Topline data were announced from a phase 3b trial evaluating the concomitant use of ixekizumab and tirzepatide in adults with active psoriatic arthritis and obesity.

The TOGETHER-PsA study shows that combining ixekizumab with tirzepatide leads to significantly better psoriatic arthritis ...

The updated guidelines encompass 7 overarching principles and 11 recommendations concerning treatment approaches and pharmacological therapies for psoriatic arthritis. The European Alliance of ...

Long-term PsA treatment may be on its way Improvements were noted in patients' physical function, enthesitis, dactylitis, and skin manifestations in a five-year trial. Golimumab, a tumor necrosis ...

Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Domain-based or treat-to-target approaches can be effective in ...